triamcinolone acetonide · Harrow Eye · NDA 022048
Triesence
Earliest generic entry, as listed
17 Dec 2029
Blocked by patent: US 8128960.
Listed patents · 3 unexpired
| Patent | Claims | Expires |
|---|---|---|
| US 8128960 | product | 17 Dec 2029 |
| US 8211880 | use U-1258 | 10 Mar 2029 |
| US 8211880 | use U-1257 | 10 Mar 2029 |
Exclusivities · 0 unexpired
No unexpired exclusivities listed.
Paragraph IV certifications · 0
No Paragraph IV certification listed by FDA for this drug.
The list shows that a generic applicant certified to FDA that a listed patent is invalid or not infringed. It does not show litigation, settlements or launch timing.
Event history
No events yet. The first ingestion only records products entering their 12-month window; changes appear from the next Orange Book update.
Products covered · 1
| NDA · product | Form | Strength | Listed expiry |
|---|---|---|---|
| 022048 · 001 · RLD | injectable, intravitreal | 40MG/ML (40MG/ML) | 17 Dec 2029 |